Androgenetic Alopecia Market projected to reach $5.76 billion by 2032, driven by aesthetic awareness

From GlobeNewswire: 2025-06-19 08:30:00

The Androgenetic Alopecia Market was valued at USD 2.81 billion in 2023 and is projected to reach USD 5.76 billion by 2032, with a CAGR of 8.33% during 2024–2032. The market is growing due to aesthetic consciousness and a rising preference for advanced therapies. In the U.S., the market was valued at USD 0.84 billion in 2023 and is expected to double by 2032, supported by increased adoption of treatment solutions.

Major players in the market include Johnson & Johnson, Merck & Co., Inc., Cipla Ltd., and more. The male market segment dominated in 2023, accounting for 58.42% of global revenue, driven by male pattern baldness. The female segment is expected to grow due to rising awareness of hormonal hair loss. Pharmaceuticals currently dominate the market, with dermatology clinics being the leading end-use setting.

North America dominated the global market in 2023, capturing 38.20% of revenue, while the Asia Pacific region is expected to witness the fastest growth. Recent developments include new generics divisions and strategic alliances for innovative treatments. Pfizer Inc. announced Phase 2 trial results for a novel topical JAK3 inhibitor for androgenetic alopecia. SNS Insider is a leading market research agency providing up-to-date market data and insights for decision-making.



Read more at GlobeNewswire: Androgenetic Alopecia Market Set to Reach USD 5.76 Billion